What type of study is this?

This is a RCT study (also classified as: Phase 2).

September 16, 2025

A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety

View Full Paper

Ask AI

Bookmark

There was no significant difference in bilateral ventral striatum activity between azetukalner and placebo.
Azetukalner showed a numerical benefit on depression and anhedonia scales compared to placebo.
The study was a randomized, double-blind, placebo-controlled trial involving 60 participants over 8 weeks.
Despite not meeting the primary endpoint, secondary outcomes indicated potential improvements in depressive symptoms.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates changes in reward response and clinical outcomes in individuals with MDD and anhedonia, suggesting azetukalner's potential benefits.

Cite This Study

Murrough et al. (2025) studied this question.

synapsesocial.com/papers/68d454c531b076d99fa59f72 https://doi.org/10.21203/rs.3.rs-7448148/v1

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates changes in reward response and clinical outcomes in individuals with MDD and anhedonia, suggesting azetukalner's potential benefits.

A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety

Key Points

Discussion

Implication

Cite This Study

A Randomized, Controlled Trial of the Novel, Potent Kv7 Channel Opener Azetukalner in Individuals with Major Depressive Disorder and Anhedonia: Neural Response to Reward, Clinical Outcomes, and Safety

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider